PEPTIC

Proton Pump Inhibitor versus Histamine-2 Receptor Blocker for Ulcer Prophylaxis

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 26,982 ventilated ICU patients, PPI prophylaxis did not change 90-day in-hospital mortality versus H₂-receptor antagonists.

26.982

Disegno

Cluster-randomised crossover trial, 50 ICUs across Australia, New Zealand, Canada, England, Ireland

Esito

90-day in-hospital mortality

Rilevanza

Risultato18.3% vs 17.5% (RR 1.05). No difference in infectious complications.

PEPTIC Investigators. JAMA. 2020;323(7):616-626. 10.1001/jama.2019.22190

Discussione e critica

Either agent acceptable; modern preference is PPI based on REVISE.